SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 4th, 2023 • AnPac Bio-Medical Science Co., Ltd. • Services-medical laboratories • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2023, between AnPac Bio-Medical Science Co., Ltd., a company incorporated under the laws of the British Virgin Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
FORM OF CERTIFICATED WARRANT]AnPac Bio-Medical Science Co., Ltd. • April 4th, 2023 • Services-medical laboratories • New York
THIS PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from AnPac Bio-Medical Science Co., Ltd., a corporation incorporated under the laws of British Virgin Islands (the “Company”), up to ______ Class A Ordinary Shares (as defined below) of the Company, represented by __________ American Depositary Shares (“ADSs”), each ADS representing twenty (20) Class A Ordinary Shares (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of a Warrant under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). ’
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 4th, 2023 • AnPac Bio-Medical Science Co., Ltd. • Services-medical laboratories • New York
This letter (the “Agreement”) constitutes the agreement by and between Univest Securities, LLC (“Univest” or the “Placement Agent”) and AnPac Bio-Medical Science Co., Ltd., a company incorporated under the laws of the British Virgin Islands (the “Company”), pursuant to which the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of American depositary shares (the “Offered ADSs”), with each American depositary share (the “ADS”) representing twenty (20) Class A ordinary shares, par value US$0.01 per share, of the Company (the “Ordinary Shares”), pre-funded warrants (the “Pre-Funded Warrants”), to purchase ADSs (the “Pre-Funded Warrant ADSs”), and warrants (the “Warrants”), to purchase ADSs (the “Warrant ADSs”) (collectively with the Offered ADSs, Warrants and Pre-Funded Warrants, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon b
